Dashboard
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 6.87%
- Poor long term growth as Net Sales has grown by an annual rate of -0.42% and Operating profit at 5.22% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.97
Flat results in Sep 26
Stock is technically in a Bearish range
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
INR 13 Cr (Micro Cap)
20.00
40
0.00%
0.17
4.55%
0.94
Total Returns (Price + Dividend) 
Desh Rakshak for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Desh Rakshak Aushdhalaya Ltd Falls to 52-Week Low of Rs 21.5 as Sell-Off Deepens
A sharp decline over the past two sessions has dragged Desh Rakshak Aushdhalaya Ltd to a fresh 52-week low of Rs 21.5 on 20 Nov 2026, marking a significant 52.5% drop over the last year and a stark contrast to the broader market’s modest losses.
Read More
Desh Rakshak Aushdhalaya Ltd Valuation Shifts Signal Renewed Price Attractiveness
Desh Rakshak Aushdhalaya Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant shift in its valuation parameters, moving from a risky to a very attractive valuation grade. Despite a stagnant share price of ₹26.90 and a challenging one-year return of -52.46%, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now suggest a compelling entry point relative to its peers and historical benchmarks.
Read More
Desh Rakshak Aushdhalaya Ltd Valuation Shifts Signal Renewed Price Attractiveness
Desh Rakshak Aushdhalaya Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a significant shift in its valuation parameters, moving from a risky to a very attractive valuation grade. Despite a stagnant share price at ₹26.90 and a challenging sector environment, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for value investors seeking opportunities in an otherwise expensive peer group.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Newspaper Publication
15-Nov-2026 | Source : BSENewspaper Publication for Unaudited Financial Results for the quarter and half year ended September 30 2026 and for notice to shareholders for opening of Special Window for Transfer and Dematerialisation of Physical Securities
Submission Of Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2026 As Per Regulation 33 Of The Securities And Exchange Board Of India (SEBI) (Listing Obligations And Disclosure Requirements) Regulations 2015
14-Nov-2026 | Source : BSEFinancial Results as per Reg 33 of the SEBI (LODR) Reg 2015
Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Para A Of Part A Of Schedule III And Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
14-Nov-2026 | Source : BSEThe Board of Directors of the Company in its meeting held on Saturday 14th day of November 2026 at the registered office of the Company has discussed considered and took noted and approved the matters as per the notice and agenda of the Board Meeting
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 0 FIIs
Tosh Kumar Jain (21.93%)
Ruchika Chaturvedi (9.65%)
49.84%
Quarterly Results Snapshot (Standalone) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 67.47% vs -75.94% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 87.50% vs -73.33% in Jun 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is -0.88% vs 17.01% in Sep 2024
Growth in half year ended Sep 2025 is -29.17% vs 84.62% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is -12.05% vs 17.90% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -27.78% vs 38.46% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 13.24% vs 4.33% in Mar 2025
YoY Growth in year ended Mar 2026 is 16.67% vs 11.63% in Mar 2025